- Home
- CYTH vs CLDI Comparison
CYTH vs CLDI Comparison
Compare CYTH & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTH
- CLDI
- Stock Information
- Founded
- CYTH 1990
- CLDI 2014
- Country
- CYTH United States
- CLDI United States
- Employees
- CYTH N/A
- CLDI N/A
- Industry
- CYTH Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CYTH Health Care
- CLDI Health Care
- Exchange
- CYTH Nasdaq
- CLDI Nasdaq
- Market Cap
- CYTH 31.9M
- CLDI 35.2M
- IPO Year
- CYTH N/A
- CLDI N/A
- Fundamental
- Price
- CYTH $0.91
- CLDI $1.05
- Analyst Decision
- CYTH Buy
- CLDI Strong Buy
- Analyst Count
- CYTH 3
- CLDI 3
- Target Price
- CYTH $0.95
- CLDI $16.67
- AVG Volume (30 Days)
- CYTH 4.5M
- CLDI 2.7M
- Earning Date
- CYTH 03-17-2025
- CLDI 03-14-2025
- Dividend Yield
- CYTH N/A
- CLDI N/A
- EPS Growth
- CYTH N/A
- CLDI N/A
- EPS
- CYTH N/A
- CLDI N/A
- Revenue
- CYTH $870,725.00
- CLDI N/A
- Revenue This Year
- CYTH N/A
- CLDI N/A
- Revenue Next Year
- CYTH $24.49
- CLDI N/A
- P/E Ratio
- CYTH N/A
- CLDI N/A
- Revenue Growth
- CYTH N/A
- CLDI N/A
- 52 Week Low
- CYTH $0.55
- CLDI $0.58
- 52 Week High
- CYTH $1.79
- CLDI $16.80
- Technical
- Relative Strength Index (RSI)
- CYTH 53.59
- CLDI 45.04
- Support Level
- CYTH $0.85
- CLDI $1.16
- Resistance Level
- CYTH $1.45
- CLDI $1.30
- Average True Range (ATR)
- CYTH 0.13
- CLDI 0.24
- MACD
- CYTH -0.00
- CLDI 0.01
- Stochastic Oscillator
- CYTH 22.83
- CLDI 40.10
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.